MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K/AKT/mTOR signaling pathway
We conclude that MRPL21 is a novel biomarker and therapeutic target of HNSCC progression and cisplatin resistant, which may provide a new approach for overcoming cisplatin resistance in HNSCC patients.
Authors
- Dapeng Lei (ORCID: https://orcid.org/0000-0001-5637-3509)
- Dongmin Wei (ORCID: https://orcid.org/0000-0001-6872-162X)
- Shengda Cao
- Ran Wei (ORCID: https://orcid.org/0000-0003-2178-5014)
- Ye Qian (ORCID: https://orcid.org/0000-0002-0731-5596)
- Feng Chen (ORCID: https://orcid.org/0000-0001-7169-9830)
- Jugao Fang (ORCID: https://orcid.org/0000-0003-1372-7228)
- Junping Liu (ORCID: https://orcid.org/0000-0001-7442-2116)
- Rui Guan (ORCID: https://orcid.org/0000-0002-4450-2817)
- Ce Li (ORCID: https://orcid.org/0000-0003-1465-4905)
- Wenming Li (ORCID: https://orcid.org/0000-0002-7638-9978)
- Jingao Li (ORCID: https://orcid.org/0000-0002-0389-7576)
- Ruijie Jiao
Institutions
- Beijing Tongren Hospital (CN)
- Shandong University (CN)
- Capital Medical University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1186/s13046-025-03482-9
- Citations
- 3
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province